Bronchoscopic ablation for non-small cell lung cancer

Area of Science:

• Pulmonology
• Oncology
• Minimally Invasive Surgery

Background:

• Bronchoscopic ablation is an emerging minimally invasive treatment for non-small cell lung cancer (NSCLC).
• Various techniques like radiofrequency ablation (RFA), microwave ablation (MWA), pulsed electric field (PEF) ablation, and cryoablation are being evaluated.
• These methods offer potential advantages over traditional percutaneous approaches.

Purpose of the Study:

• To review the current status and potential of bronchoscopic ablation techniques for NSCLC.
• To assess the safety, efficacy, and emerging immune-related effects of these minimally invasive treatments.
• To identify the need for further research and larger clinical trials.

Main Methods:

• Review of feasibility and early clinical studies on bronchoscopic ablation modalities (RFA, MWA, PEF, cryoablation).
• Evaluation of technical success, safety profiles, and complication rates.
• Assessment of local tumor control and potential systemic anti-cancer immune responses.

Main Results:

• Bronchoscopic ablation techniques demonstrate technical success with encouraging safety and reduced complications compared to percutaneous methods.
• RFA and MWA show effective tumor ablation, but isolated mortality events require further safety evaluation.
• PEF ablation preserves surrounding structures and may activate immune responses; cryoablation shows feasibility with minimal adverse events.
• Emerging evidence suggests these treatments can stimulate systemic anti-cancer immunity, potentially synergizing with immunotherapy.

Conclusions:

• Bronchoscopic ablation is a developing therapeutic option for NSCLC, offering lung-sparing advantages.
• Further large-scale prospective trials are necessary to establish long-term efficacy, safety, and optimal techniques.
• These techniques hold promise for complementing evolving immunotherapy paradigms in lung cancer treatment.